NovoCure Ltd
Company Profile
Business description
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Contact
Grenville Street
No. 4 The Forum, Second Floor
St. HelierJE2 4UF
JEYT: +44 1534756700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
1,605
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,173.60 | 36.60 | -0.40% |
| CAC 40 | 8,276.55 | 1.98 | 0.02% |
| DAX 40 | 24,162.41 | 95.71 | 0.40% |
| Dow JONES (US) | 48,505.53 | 41.81 | 0.09% |
| FTSE 100 | 10,591.16 | 31.58 | 0.30% |
| HKSE | 26,394.26 | 521.94 | 2.02% |
| NASDAQ | 24,076.63 | 60.62 | 0.25% |
| Nikkei 225 | 59,518.34 | 1,640.95 | 2.84% |
| NZX 50 Index | 13,066.06 | 48.80 | 0.37% |
| S&P 500 | 7,038.22 | 15.27 | 0.22% |
| S&P/ASX 200 | 8,955.00 | 56.40 | -0.63% |
| SSE Composite Index | 4,055.55 | 28.34 | 0.70% |